Analysis of Related Risk Factors of Microvascular Invasion in Hepatocellular Carcinoma

Comput Math Methods Med. 2022 Mar 21:2022:8195512. doi: 10.1155/2022/8195512. eCollection 2022.

Abstract

Objective: To forecast the onset of microvascular invasion (MVI) in patients with hepatoma by evaluating the preoperative aspartate aminotransferase-to-platelet ratio index (APRI), alpha-fetoprotein (AFP), neutrophil-to-lymphocyte ratio (NLR), and other clinicopathological data.

Methods: In this study, we retrospectively analysed the clinical data of 62 patients who received radical surgery for hepa toma from 2019 to 2021. Patients were separated into the MVI-negative group and the MVI-positive group according to the postoperative pathological diagnosis. The relationships between MVI and NLR, APRI, AFP, tumor size, and other clinical data were assessed using the univariate analysis, receiver operating characteristic (ROC) curve, least absolute shrinkage and selection operator (LASSO) analysis, and logistic analysis.

Results: The ROC curve determined that the cutoff values of NLR, platelet-to-lymphocyte ratio (PLR), and APRI were 1.520, 98, and 0.275, respectively. The univariate analysis showed that the MVI-positive result was associated with five factors: tumor size (χ 2 = 10.620, p = 0.001), AFP (χ 2 = 10.524, p = 0.001), Edmondson grade (χ 2 = 20.736, p < 0.001), NLR (χ 2 = 8.744, p = 0.003), and APRI (χ 2 = 4.849, p = 0.028). The LASSO analysis indicated that the risk factors were the number of tumors, PLR, APRI, NLR, AFP, Edmondson grade, and tumor size. The multivariate logistic regression analysis showed that NLR ≥ 1.520 (OR 11.119, p = 0.006), APRI ≥ 0.275 (OR 12.515, p = 0.009), AFP ≥ 200 μg/mL (OR 7.823, p = 0.016), and tumor size > 3 cm (OR 7.689, p = 0.022) were independent risk factors for MVI in patients with hepatoma.

Conclusion: Preoperative NLR, APRI, AFP, and tumor size are reliable indicators for predicting the appearance of MVI in patients with hepatoma and are of great value in making detailed and reliable treatment protocols for these patients before surgery.

Publication types

  • Retracted Publication

MeSH terms

  • Carcinoma, Hepatocellular* / surgery
  • Humans
  • Liver Neoplasms* / pathology
  • Liver Neoplasms* / surgery
  • Lymphocytes / pathology
  • Retrospective Studies
  • Risk Factors